Search research articles
Contact Us
Filters
Showing results (101-110 of 179) with videos related to
Page
of 18
Sort By:
JAMA Network Open
|
June 6, 2022
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
Yufei Liu, Zhe Zhang, Waree Rinsurongkawong, et al.
Future Oncology (London, England)
|
December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance
Egbert F Smit, Christophe Dooms, Jo Raskin, et al.
JCO Precision Oncology
|
December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping
Xiuning Le, Lingzhi Hong, Chuck Hensel, et al.
Clinical Lung Cancer
|
October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Arxiv
|
December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer Research
Amgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Cancers
|
March 13, 2024
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Kang Qin, Kaiwen Wang, Shenduo Li, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2020
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype
Monique B Nilsson, Jacqulyne Robichaux, Matthew H Herynk, et al.
Research Square
|
June 3, 2024
CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning
Muhammad Aminu, Bo Zhu, Natalie Vokes, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 179) with videos related to
Sort By:
Page
of 18
JAMA Network Open
|
June 6, 2022
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
Yufei Liu, Zhe Zhang, Waree Rinsurongkawong, et al.
Future Oncology (London, England)
|
December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i>-amplified NSCLC and first-line osimertinib resistance
Egbert F Smit, Christophe Dooms, Jo Raskin, et al.
JCO Precision Oncology
|
December 27, 2021
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping
Xiuning Le, Lingzhi Hong, Chuck Hensel, et al.
Clinical Lung Cancer
|
October 22, 2018
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC)
Yasir Y Elamin, Daniel R Gomez, Mara B Antonoff, et al.
Arxiv
|
December 25, 2025
From Classical Machine Learning to Emerging Foundation Models: Review on Multimodal Data Integration for Cancer Research
Amgad Muneer, Muhammad Waqas, Maliazurina B Saad, et al.
Cancers
|
March 13, 2024
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Kang Qin, Kaiwen Wang, Shenduo Li, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Isamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer
|
August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)
Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2020
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype
Monique B Nilsson, Jacqulyne Robichaux, Matthew H Herynk, et al.
Research Square
|
June 3, 2024
CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning
Muhammad Aminu, Bo Zhu, Natalie Vokes, et al.
Page
of 18